Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
940.00    4.00 (0.43%)
Bid:
932.00
Ask:
946.00
Spread: 14.00 (1.502%)
Market Cap: £257.28m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Full Year Trading Update

4 Oct 2017 07:00

RNS Number : 6174S
Gooch & Housego PLC
04 October 2017
Β 

For immediate release

4 October 2017

Β 

Β 

Gooch & Housego PLC

("G&H" or the "Company")

Β 

Full Year Trading Update

Β 

"Trading in line with expectations"

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components & systems, today announces that trading for the year ended 30 September 2017 is in line with its previous guidance. The Company expects to announce its audited results for the year ended 30 September 2017 on 28 November 2017.

During the financial year ended 30 September 2017, the business has benefited from positive market conditions and strong demand in its industrial and telecommunications sectors, in particular critical components used in microelectronic manufacturing and high reliability undersea fibre couplers.

Β 

G&H has started its new financial year with a record year end order book, which, as at 30 September 2017, stood at Β£72.2 million, an increase of 36.7% compared with the same time last year. Excluding the impact of foreign exchange and acquisitions this represents an increase of 29.2% on the starting order book last year.

Β 

Approximately one third of our business now relates to the Aerospace & Defence ("A&D") sector, due in part to the acquisitions made in FY 2016 and FY 2017.

Β 

In February 2017 the Company acquired StingRay Optics LLC ("StingRay"), a USA based specialist designer and manufacturer of high performance optical and opto-mechanical sub-systems for demanding defence and commercial applications. StingRay has integrated well into the wider business and has performed strongly since acquisition, contributing positively to the overall results of G&H in FY 2017.

Β 

Our performance improvement programme has made positive progress. There has been continued benefit from concentrating our Research and Development ("R&D") efforts on fewer higher return projects and from enhanced business development activity. We have invested in our skills base, the latest manufacturing equipment, improved lean processes and business systems and we intend to continue to do so in order to support our future growth.

The Company remains in a strong financial position and will make further investment in the business.

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"G&H is well positioned to take advantage of the positive market conditions and we continue to invest in people, processes, systems and capital equipment to meet the demands of a robust order book.

"We remain committed to further diversification of the business and moving up the value chain. This has been most evident in the A&D sector, where recent acquisitions and investment in R&D has taken us closer to establishing 'critical mass' in this sector.

"We will continue to invest in our performance improvement plan which we believe will underpin our future growth."

Β 

Β 

For further information contact: -

Β 

Mark Webster / Andrew Boteler

Gooch & Housego PLC

01460 256440

Mark Court / Sophie Cowles

Buchanan

020 7466 5000

Patrick Robb / David Anderson

Investec Bank plc

020 7597 5970

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Notes to editors

Β 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

Β 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTFSAFADFWSEIS
Date   Source Headline
23rd Jul 20127:00 amRNSProgress Update
12th Jun 20127:00 amRNSInterim Results
22nd May 20127:00 amRNSNotification of Interim Results
5th Apr 20127:00 amRNSHalf-Year Trading Update
14th Mar 20128:59 amRNSAIM Rule 20 - Annual Report
23rd Feb 201212:45 pmRNSAppointment of non-executive director
23rd Feb 20127:00 amRNSResults of Annual General Meeting
21st Feb 20127:00 amRNSTrading Update
29th Nov 20117:00 amRNSPreliminary Results
4th Nov 20114:35 pmRNSPrice Monitoring Extension
4th Oct 20117:00 amRNSFull-Year Trading Update
29th Sep 201111:52 amRNSBoard Change
8th Jun 20117:00 amRNSInterim Results
12th May 201112:24 pmRNSNotice of Results
1st Apr 20117:00 amRNSAcquisition and Trading Update
23rd Feb 20117:00 amRNSProgress Update for Today's Annual General Meeting
28th Jan 20118:10 amRNSDirector/PDMR Shareholding
25th Jan 20118:30 amRNSAcquisition of EM4
24th Jan 201112:07 pmRNSAdditional Listing
19th Jan 201111:45 amRNSUS Regulatory Approval
13th Jan 20114:55 pmRNSNotification of Interests
13th Jan 20114:55 pmRNSDirector Shareholdings
13th Jan 20114:53 pmRNSAdditional Listing
5th Jan 20111:42 pmRNSResult of EGM
16th Dec 20102:37 pmRNSProposed Acquisition, Placing and General Meeting
2nd Dec 20108:52 amRNSDividend
30th Nov 20107:00 amRNSPreliminary Results
15th Nov 20107:00 amRNSNotice of Results
5th Oct 20107:00 amRNSFull-Year Trading Update
17th Sep 20102:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSTrading Update
8th Jun 20107:00 amRNSInterim Results
18th May 20107:00 amRNSNotice of Results
8th Apr 20107:00 amRNSHalf-Year Trading Update
26th Mar 20103:33 pmRNSHolding(s) in Company
12th Mar 20108:56 amRNSDirector/PDMR Shareholding
25th Feb 201011:00 amRNSResult of AGM
24th Feb 20107:00 amRNSProgress Update for Today's Annual General Meeting
26th Jan 20108:24 amRNSDirector/PDMR Shareholding
18th Jan 20103:48 pmRNSAward of Share Options
7th Jan 20103:09 pmRNSAward of share-based incentives
1st Dec 20097:00 amRNSPreliminary Results
12th Nov 20098:56 amRNSNotice of Results
6th Oct 20097:00 amRNSFull-Year Trading Update
23rd Jul 20097:00 amRNSAppointment of new executive director
9th Jun 20097:00 amRNSInterim Results
13th May 20098:57 amRNSNotice of Results
2nd Apr 20097:00 amRNSResult of AGM
31st Mar 20097:00 amRNSHalf-Year Trading Update
23rd Mar 20097:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.